Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
11.37
+0.22 (1.97%)
Sep 18, 2025, 12:41 PM EDT - Market open
Greenwich LifeSciences Employees
As of December 31, 2024, Greenwich LifeSciences had 8 total employees, including 4 full-time and 4 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$2,249,072
Market Cap
154.98M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | 1 | 14.29% |
Dec 31, 2023 | 7 | 1 | 16.67% |
Dec 31, 2022 | 6 | 0 | - |
Dec 31, 2021 | 6 | 3 | 100.00% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GLSI News
- 7 hours ago - Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland - GlobeNewsWire
- 8 days ago - Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation - GlobeNewsWire
- 4 weeks ago - Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences - GlobeNewsWire
- 4 weeks ago - Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team - GlobeNewsWire
- 5 weeks ago - Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania - GlobeNewsWire
- 5 weeks ago - Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events - GlobeNewsWire
- 6 months ago - Greenwich LifeSciences Provides Global Update on FLAMINGO-01 - GlobeNewsWire
- 6 months ago - Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - GlobeNewsWire